Analyst Jill Wu Raises Target Price and Reiterates Buy on Innovent Biologics After Strong 1H26 Beat and Robust Growth Outlook
Tip Ranks·- CMB International Securities analyst Jill Wu maintained a Buy rating on Innovent Biologics and raised the price target to HK$ 130.25 following a strong 1H26 earnings beat. - The positive rating is driven by robust product sales, expanding global presence, promising pipeline assets, and strategic alliances with Takeda and Pfizer. - These factors, alongside upcoming clinical and regulatory milestones, reinforce confidence in meeting management's long-term revenue targets for 2027 and 2030.